To this end, the development of recombinant kynureninases aims to enzymatically deplete the extracellular pool of Kyn to limit its intracellular availability, thus hampering the Kyn-AhR interaction that promotes tumor-associated immunosuppression (106–108). This evidence concerns the gene KYNU and neoplasm.